Your session is about to expire
← Back to Search
ABSK-021 for Cancer
Study Summary
This trial is testing a new drug to see if it is safe and works well against cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals have enrolled in this research endeavor?
"Affirmative. As evidenced by information on clinicaltrials.gov, this medical investigation has been actively recruiting since 20th January 2020 and last updated 25th July 2022. Eighty-five patients are being sought from three different centres of research."
Is there still an opportunity to join this experiment?
"As per the clinicaltrials.gov listing, this research endeavor is currently in search of participants since its initial posting on January 20th 2020 and most recent edit on July 25th 2022."
Has ABSK021 obtained the regulatory seal of approval from the US Food and Drug Administration?
"Due to the limited clinical data available, ABSK021 is assessed as having a safety rating of 1. This assessment derives from it being classified in Phase 1 of this medical trial."
What is the primary objective of this experiment?
"Over the study's 6-month duration, the primary outcome of interest is to measure Incidence of DLTs. Secondary outcomes include Disease Control Rate (DCR), Progression-Free Survival (PFS), and Duration of Response (DoR)."
Share this study with friends
Copy Link
Messenger